27 November 2017 - Swedish Orphan Biovitrum (Sobi) has received approval from Health Canada for an oral suspension formulation of Orfadin (nitisinone). 

Orfadin is a medicine approved in multiple countries across North America and Europe for use in combination with dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinaemia type 1 (HT-1), a rare genetic disorder that can cause liver, renal and neurological complications and in most cases is fatal if untreated.

Both Orfadin oral suspension and Orfadin 20 mg capsules are available in Canada, as well as the original 2 mg, 5 mg and 10 mg capsules.

Read Sobi press release